YOLFTbeta
Vera Therapeutics Inc

Vera Therapeutics Inc

VERA · NASDAQ · Healthcare / Biotechnology

28.10USD-0.94 (-3.24%)

Price History

Full chart

Market Stats

Previous Close29.04
Open28.64
Day Range27.85 – 28.96
52-Week Range23.05 – 56.05
Volume1.01M
Market Cap2.34B
P/E (TTM)0.00
Forward P/E0.00
EPS-5.87
Dividend Yield0.00%
Beta0.95
50-Day Avg33.49
200-Day Avg39.34

About

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Marshall W. Fordyce M.D.
  • Employees361
  • Headquarters2000 Sierra Point Parkway, Brisbane, CA, United States, 94005, USA
  • Websitehttps://veratx.com

Leadership

  • Dr. Marshall W. Fordyce M.D.Founder, President, CEO & Director · b. 1975
  • Mr. Sean P. Grant M.B.A.Chief Financial Officer · b. 1985
  • Mr. David L. Johnson M.B.A.Chief Opearating Officer · b. 1970
  • Dr. Robert M. Brenner M.D.Chief Medical Officer · b. 1968
  • Mr. Joseph R. Young M.B.A.Senior VP of Finance & Chief Accounting Officer · b. 1972
  • Ms. S. Sandra Park J.D.Senior VP of Legal, Healthcare,Commercial Law, Compliance & Operations
  • Dr. Jane Wright-Mitchell J.D., Pharm.D.Chief Legal Officer & Secretary · b. 1969
  • Ms. Debra CharlesworthVice President of Corporate Communications
  • Ms. Emma HaywoodVice President of Marketing
  • Mr. Tom DoanExecutive Vice President of Development Operations · b. 1972

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue00001.86M00
Growth (%)------100.00%-
Cost of Revenue509.00K251.00K176.00K-846.00K-1.86M2.17M468.00K
Gross Profit-509.00K-251.00K-176.00K846.00K1.86M-2.17M-468.00K
Gross Margin----100.00%--
Operating Expense11.45M47.81M34.23M91.75M103.87M165.00M315.00M
Operating Income-11.96M-48.06M-34.40M-90.90M-102.01M-167.17M-315.47M
Operating Margin-----5478.63%--
EBITDA-11.29M-52.99M-34.23M-91.75M-92.18M-144.42M-291.62M
EBITDA Margin-----4950.70%--
Net Income-11.85M-53.41M-32.61M-89.06M-95.99M-152.15M-299.62M
Net Income Margin-----5155.21%--
R&D7.29M43.92M22.48M68.99M78.22M126.17M215.26M
R&D as % of Total Revenue----4201.13%--
Interest Expense51.00K166.00K20.00K992.00K3.79M7.63M7.53M
Interest Expense % of Total Revenue----203.33%--

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets5.38M54.55M83.75M131.44M175.55M655.68M734.73M
Total Liabilities41.93M143.90M14.16M54.53M73.86M78.53M130.21M
Total Equity-36.55M-89.35M69.59M76.91M101.69M577.15M604.52M
Cash3.19M53.65M79.67M43.46M45.68M92.65M354.73M
Total Debt132.00K2.00K4.92M31.29M53.71M54.64M77.31M
Net Debt-3.06M-53.65M-74.75M-12.17M8.03M-38.01M-277.42M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-10.29M-34.81M-23.71M-67.60M-92.18M-134.68M-241.10M
Investing Cash Flow-125.00K-42.00K-4.20M-70.55M-39.43M-425.03M194.29M
Financing Cash Flow-137.00K85.29M53.88M101.93M133.54M606.67M308.90M
Capital Expenditure125.00K99.00K062.00K63.00K972.00K630.00K
Free Cash Flow-10.41M-34.91M-23.71M-67.66M-92.24M-135.65M-241.73M
FCF to OCF101.21%100.28%100.00%100.09%100.07%100.72%100.26%

Earnings

Report DateMar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Jun 24, 2021Aug 16, 2021Nov 10, 2021Mar 24, 2022May 16, 2022Aug 10, 2022Nov 9, 2022Mar 28, 2023May 11, 2023Aug 10, 2023Nov 9, 2023Mar 20, 2024May 9, 2024Aug 8, 2024Nov 7, 2024Feb 26, 2025May 6, 2025Aug 5, 2025Nov 5, 2025Feb 26, 2026May 7, 2026Aug 10, 2026Nov 4, 2026
EPS Estimate-----1.94-0.45-0.59-0.46-0.64-0.78-0.90-0.90-0.45-0.74-0.54-0.51-0.53-0.54-0.62-0.81-0.78-0.62-1.20-1.34-1.37-1.60-1.72
EPS Actual-0.12-0.17-0.21-2.02-12.23-0.33-0.36-0.79-0.71-0.55-0.91-1.18-0.80-0.46-0.45-0.58-0.56-0.62-0.85-0.72-0.81-1.20-1.26-1.39-1.69-1.52-
Surprise-----530.41%26.67%38.98%-71.74%-10.94%29.49%-1.11%-31.11%-77.78%37.84%16.67%-13.73%-5.66%-14.81%-37.10%11.11%-3.85%-93.55%-5.00%-3.73%-23.36%5.00%-
Timing----Pre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market-Pre-marketAfter-hours-

Key Statistics & Ratios

Market Cap2.34B
Enterprise Value1.96B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book5.84
EPS-5.87
Book Value5.67
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-415.22M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-91.75%
Return on Assets-46.76%
Shares Outstanding72.06M
Shares Float52.39M
Beta0.95
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 14 analystsTarget 77.50
  • Strong Buy
    9
  • Buy
    4
  • Hold
    1

Ownership Breakdown

Institutions
117.95%
Insiders
0.95%
Retail / Other
0.00%

Top Institutional Holders

  • venBio Select Advisor LLC
    5.89M8.17%
  • BlackRock Inc
    5.09M7.06%
  • T. Rowe Price Associates, Inc.
    4.57M6.35%
  • Deep Track Capital, LP
    4.00M5.55%
  • Deerfield Management Co
    3.72M5.17%
  • State Street Corp
    3.36M4.67%
  • Kynam Capital Management, LP
    2.89M4.01%
  • Sofinnova Ventures
    2.79M3.88%
  • Vanguard Capital Management, LLC
    2.68M3.72%
  • FMR Inc
    2.68M3.71%
  • Eversept Partners, LP
    2.21M3.07%
  • Logos Global Management LP
    2.20M3.05%
  • Integral Health Asset Management, LLC
    1.75M2.43%
  • Bellevue Group AG
    1.71M2.37%
  • Geode Capital Management, LLC
    1.57M2.18%
  • Vestal Point Capital LP
    1.37M1.90%
  • AllianceBernstein L.P.
    1.31M1.82%

Top Fund Holders

  • State Street® SPDR® S&P® Biotech ETF
    2.79M3.87%
  • Vanguard MStar Total Stk Mkt Idx Invest
    1.94M2.69%
  • iShares Russell 2000 ETF
    1.64M2.28%

Dividends

19961×
0.02Jan 10, 1996
19952×
0.02Jun 30, 19950.02Jan 17, 1995
19942×
0.02Jun 13, 19940.02Jan 4, 1994
19931×
0.02Jun 10, 1993
19922×
0.02Dec 8, 19920.02Jun 4, 1992
19912×
0.02Dec 4, 19910.02May 30, 1991
19902×
0.02Dec 11, 19900.02May 25, 1990